Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 420

1.

MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB.

PLoS One. 2009 Oct 2;4(10):e7314. doi: 10.1371/journal.pone.0007314.

PMID:
19798417
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.

Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH.

BMC Cancer. 2010 Sep 15;10:493. doi: 10.1186/1471-2407-10-493.

PMID:
20843305
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.

Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.

PMID:
22282309
[PubMed - indexed for MEDLINE]
Free Article
4.

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.

Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA.

Clin Cancer Res. 2008 Jul 1;14(13):4067-78. doi: 10.1158/1078-0432.CCR-07-4959.

PMID:
18593983
[PubMed - indexed for MEDLINE]
Free Article
5.

[Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].

Zhang Q, He XJ, Ma LP, Li N, Yang J, Cheng YX, Cui H.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):885-90. Chinese.

PMID:
22340095
[PubMed - indexed for MEDLINE]
6.

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET.

J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000.

PMID:
12096084
[PubMed - indexed for MEDLINE]
Free Article
7.

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG.

BMC Cancer. 2008 Jan 22;8:17. doi: 10.1186/1471-2407-8-17.

PMID:
18208621
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.

Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB, Feng Q.

World J Surg Oncol. 2012 Aug 27;10:174.

PMID:
22925189
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

MicroRNA expression profiles in serous ovarian carcinoma.

Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S.

Clin Cancer Res. 2008 May 1;14(9):2690-5. doi: 10.1158/1078-0432.CCR-07-1731.

PMID:
18451233
[PubMed - indexed for MEDLINE]
Free Article
10.

Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.

Piek JM, Torrenga B, Hermsen B, Verheijen RH, Zweemer RP, Gille JJ, Kenemans P, van Diest PJ, Menko FH.

Fam Cancer. 2003;2(2):73-8.

PMID:
14574155
[PubMed - indexed for MEDLINE]
11.

Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.

McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, Wei JJ.

Mod Pathol. 2012 Dec;25(12):1644-53. doi: 10.1038/modpathol.2012.118. Epub 2012 Jul 13.

PMID:
22790015
[PubMed - indexed for MEDLINE]
Free Article
12.

BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.

Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA.

Am J Surg Pathol. 2013 Jan;37(1):138-46. doi: 10.1097/PAS.0b013e31826cabbd.

PMID:
23232854
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ.

Cancer Res. 2005 Nov 15;65(22):10602-12.

PMID:
16288054
[PubMed - indexed for MEDLINE]
Free Article
14.

Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.

Espinosa I, Catasus L, Canet B, D'Angelo E, Muñoz J, Prat J.

Mod Pathol. 2011 Jun;24(6):846-54. doi: 10.1038/modpathol.2011.12. Epub 2011 Feb 11.

PMID:
21317880
[PubMed - indexed for MEDLINE]
Free Article
15.

Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.

George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, Virtanen C, Shaw PA.

J Pathol. 2011 Sep;225(1):106-17. doi: 10.1002/path.2927. Epub 2011 Jul 8.

PMID:
21744340
[PubMed - indexed for MEDLINE]
16.

MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.

Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, Hernando E, Wei JJ.

J Pathol. 2012 Oct;228(2):204-15. doi: 10.1002/path.4000. Epub 2012 Apr 18.

PMID:
22322863
[PubMed - indexed for MEDLINE]
17.

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM.

J Pathol. 2010 Feb;220(3):392-400. doi: 10.1002/path.2659.

PMID:
19967725
[PubMed - indexed for MEDLINE]
18.

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.

Salani R, Kurman RJ, Giuntoli R 2nd, Gardner G, Bristow R, Wang TL, Shih IM.

Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91. Epub 2007 Aug 10.

PMID:
17692090
[PubMed - indexed for MEDLINE]
19.

Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.

Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, Welcsh P, Goff BA, Swisher EM.

Neoplasia. 2010 Dec;12(12):993-1002.

PMID:
21170264
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, Anderson ML.

Cancer Res. 2010 Mar 1;70(5):1906-15. doi: 10.1158/0008-5472.CAN-09-3875. Epub 2010 Feb 23.

PMID:
20179198
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk